Linked Life Data

17581108

Source:http://linkedlifedata.com/resource/pubmed/id/17581108

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2007-8-2
pubmed:abstractText
Despite the demonstrated efficacy of three different classes of biologic response modifiers (BRMs) for the treatment of rheumatoid arthritis (RA), there are currently no clinical predictors or biomarkers that can rationally guide physicians in the selection of BRMs for individual patients. One promising area of translational research for patients with RA is the field of pharmacogenetics. In the absence of industry-sponsored pharmacogenetic studies of BRMs, longitudinal clinical registries may represent the most promising setting for identifying genetic biomarkers. This review focuses on published pharmacogenetic studies of TNF antagonists and discusses related methodologic issues for pharmacogenetic research using clinical registries.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1936-9719
pubmed:author
pubmed:issnType
Print
pubmed:volume
65
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
139-42
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Predicting response to TNF antagonists in rheumatoid arthritis: the promise of pharmacogenetics research using clinical registries.
pubmed:affiliation
NYU Hospital for Joint Diseases, New York, NY 10003, USA.
pubmed:publicationType
Journal Article